Galmed Pharmaceuticals
GLMD
18 hedge funds and large institutions have $8.36M invested in Galmed Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.
6% less capital invested
Capital invested by funds: $8.93M → $8.36M (-$575K)
10% less funds holding
Funds holding: 20 → 18 (-2)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.5K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$41.7K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$41.7K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$13.9K |
| 5 |
Morgan Stanley
New York
|
+$13.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAD
Craig A. Drill
|
-$904K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$121K |
| 3 |
SIM
Spark Investment Management
New York
|
-$111K |
| 4 |
Goldman Sachs
New York
|
-$55.7K |
| 5 |
Renaissance Technologies
New York
|
-$55.7K |
GLMD Hedge Fund Activity: Q2 2015 in Review
18 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2015, worth a combined $8.36M — down 6.4% from $8.93M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GLMD and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $83.5K. The largest seller was Craig A. Drill, cutting an estimated $904K.
- 18 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2015, down from 20 in Q1 2015.
- Funds reported $8.36M of Galmed Pharmaceuticals stock for Q2 2015, down 6.4% quarter-over-quarter.
- 2 funds opened new Galmed Pharmaceuticals positions in Q2 2015 and 4 closed out, a net change of -2 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2015 was Vanguard Group, an estimated $83.5K added.
- The largest Galmed Pharmaceuticals seller in Q2 2015 was Craig A. Drill, an estimated $904K sold.
Based on aggregated 13F filings for Q2 2015.